Cardiff Oncology, Inc. (CRDF)

[abracky]

TrovaGene (TROV) Upgraded by ValuEngine to “Buy”

Posted by Lisa Matthews on Nov 9th, 2018
inShare

TrovaGene Inc logoValuEngine upgraded shares of TrovaGene (NASDAQ:TROV) from a hold rating to a buy rating in a report released on Thursday, November 1st.

TROV has been the subject of several other reports. Maxim Group reaffirmed a buy rating on shares of TrovaGene in a research report on Monday, August 6th. Zacks Investment Research upgraded TrovaGene from a sell rating to a hold rating in a report on Saturday, September 29th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $4.75.
Get TrovaGene alerts:

NASDAQ:TROV traded down $0.01 on Thursday, reaching $0.79. The company’s stock had a trading volume of 299,100 shares, compared to its average volume of 787,113. TrovaGene has a 1-year low of $0.65 and a 1-year high of $8.40. The stock has a market cap of $13.27 million, a price-to-earnings ratio of -0.12 and a beta of 0.14.

TrovaGene (NASDAQ:TROV) last posted its earnings results on Wednesday, November 7th. The medical research company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.15. TrovaGene had a negative return on equity of 188.93% and a negative net margin of 2,970.66%. The firm had revenue of $0.09 million during the quarter.

An institutional investor recently raised its position in TrovaGene stock. Renaissance Technologies LLC raised its holdings in TrovaGene Inc (NASDAQ:TROV) by 58.4% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 203,802 shares of the medical research company’s stock after buying an additional 75,131 shares during the period. Renaissance Technologies LLC owned about 1.15% of TrovaGene worth $157,000 at the end of the most recent quarter. 8.89% of the stock is owned by institutional investors and hedge funds.